Download the presentation here: PDF

More documents

Recommendations

Info

A Better NSAID: Topicals 28 The appeal of a topical product lies very clearly in perceived safety advantages over systemic agents. Topical NSAIDs have enjoyed a long history in Europe, but are just entering the US market. On the market in the US: • Flector patch (1.3% diclofenac; Alpharma – acquired by King) • Voltaren Gel (1% diclofenac; Endo) In development: • Diclofenac patch (Phase II/IIIl; Cerimon) • Pennsaid Diclofenac in DMSO (Approvable in US, marketed in Canada; Nuvo) • Ketoprofen cream (Phase III; Transdel) • Nanoemulsion diclofenac (Phase II; Pharmos) • Diractin, Ketoprofen in Transferome gel (Phase III; Alpharma) • Thermoprofen, heat-assisted ketoprofen (Phase III; Zars) • TPM Diclofenac (Pre-clin; Phosphagenics) Adis R&D Insight; Company web sites © Defined Health, 2009 Pain Insight Briefing
The First-to-Market Topical NSAIDs are Off to a Good Start And have taken some of the regulatory and market risk out of the equation … but growth is flattening. How many topical NSAIDs will the US market support? 29 © Defined Health, 2009 Pain Insight Briefing
Page 1 and 2: Game Changing Plays in the Pain Mar
Page 3 and 4: Our Disclaimer 3 The information in
Page 5 and 6: Everyone Hurts “Pain is whatever
Page 7 and 8: It’s A Big Market with a Few Domi
Page 9 and 10: $ Millions But Few “Big Pharma-Si
Page 11 and 12: Pain Historically: Drug Delivery ha
Page 13 and 14: It’s Getting Tougher Labopharm La
Page 15 and 16: The Risk : Reward Profile for Novel
Page 17 and 18: Current Standard of Care for Pain
Page 19 and 20: Leaving Plenty of Unmet Need to Be
Page 21 and 22: In the Meantime, Let’s Teach Old
Page 23 and 24: A Better NSAID: NicOx • Naproxcin
Page 25 and 26: A Better NSAID: NicOx 25 Company pr
Page 27: A Better NSAID: Pozen / AstraZeneca
Page 31 and 32: Even So, Flector is Expected To Be
Page 33 and 34: Now We Have a Patch and a Gel Volta
Page 35 and 36: The Need is Clear 35 © Defined Hea
Page 37 and 38: Progenics / Wyeth: Making Opioids M
Page 39 and 40: Adolor / Pfizer: Making Opioids Mor
Page 41 and 42: Like All Things CNS, It’s Not So
Page 43 and 44: A New, and Better Opioid from J&J /
Page 45 and 46: A New, and Better Opioid from J&J /
Page 47 and 48: Opioid Abuse Deterrence 47 © Defin
Page 49 and 50: King Pharmaceuticals: Making Big Be
Page 51 and 52: But Also Significant Hurdles • Te
Page 53 and 54: The Technologies are Not the Proble
Page 55 and 56: The Real Issue is Risk Management
Page 57 and 58: Fentanyl: Again, REMS is the Big Re
Page 59 and 60: Lessons from Fentora 59 What the FD
Page 61 and 62: For Some Mechanisms, the US Regulat
Page 63 and 64: FAAH Pipeline 63 Compound SSR 10101
Page 65 and 66: FAAH Pipeline KDS-4103, acquired by
Page 67 and 68: Addressing the Big Problem 67 >50%
Page 69 and 70: New MOA Challenges 69 NeuroDiscover
Page 71 and 72: New MOA Challenges 71 The identific
Page 73 and 74: TRPV1 • The transient receptor po
Page 75 and 76: TRPV1: Target for Novel Analgesics
Page 77 and 78: TRPV1 Antagonists: Hot … Too Hot
Page 79 and 80:
TRPV1 Antagonist Pipeline Compound
Page 81 and 82:
TRPV1 Antagonist Pipeline 81 Compou
Page 83 and 84:
TRPV3: Hopeful, But Too Early to Te
Page 85 and 86:
Good Phase III Data, An Accepted ND
Page 87 and 88:
Pfizer Pursuing Multiple Chronic Pa
Page 89 and 90:
Concerning, but Transient Adverse E
Page 91 and 92:
Will NGF for Pain Be Like TNF is fo
Page 93 and 94:
Repurposed anti-TNF Antibodies for
Page 95 and 96:
What’s Next for Pain? • Continu
show all

Download the presentation here: PDF

Create successful ePaper yourself

Delete template?

Save as template?